Gamma-Hydroxybutyrate for Health & Longevity - Quick Reference Sheet

Gamma-Hydroxybutyrate for Health & Longevity

Created on 10/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Muse 1.0 – Audit

Gamma-hydroxybutyrate is a tightly restricted prescription medication taken at night for defined disorders of severe daytime sleepiness. It deepens early-night sleep and reduces next-day sleepiness in those disorders. In healthy adults, no study shows longer life, slower aging, stronger muscles, or better thinking. Harms include confusion, morning impairment, slowed breathing with alcohol or other sedatives, dependence, and severe illness on stopping. (Full Review)

Protocol

No longevity protocol
No dose, schedule, or duration established
No expert or clinic longevity protocol was identified; established protocols are disease-treatment regimens
Narcolepsy, twice-nightly oxybate
4.5 g per night in two equal doses
Two doses 2.5–4 hours apart, increasing by 1.5 g weekly toward 6–9 g
Best time of day
At bedtime, after getting into bed
Sedation begins rapidly
Time to effect
Reduced excessive daytime sleepiness
Several weeks
Stable daytime benefit typically follows several weeks of titration
Increased slow-wave sleep
First treatment night
Sedation and deeper early-night sleep begin on the first treatment night
Weight loss in narcolepsy
Thirteen weeks
Modest weight loss over thirteen weeks in adults with narcolepsy

Benefits

Contraindications
  • Alcohol
  • Sedative hypnotics (zolpidem, eszopiclone, temazepam)
  • Gamma-butyrolactone and 1,4-butanediol
  • Succinic semialdehyde dehydrogenase deficiency
  • Untreated sleep apnea or significantly compromised breathing
  • Current or past substance misuse
  • Depression or prior suicidal thinking
Key Interactions
  • Other central nervous system depressants (benzodiazepines such as clonazepam, opioids such as oxycodone, sedating muscle relaxants)
  • Divalproex and valproate
  • Sedating over-the-counter antihistamines (diphenhydramine, doxylamine)
  • Sedating supplements and related substances (melatonin, valerian, kava, phenibut)
  • Wake-promoting and stimulant medicines (modafinil, methylphenidate)
  • General anesthesia and procedural sedation

Risk & Side Effects

  • High: Nausea and vomiting; dizziness and headache
  • Medium: Enuresis and other parasomnias; sedation, confusion, and impaired alertness after dosing; tremor
  • Low: Respiratory depression, coma, and death in overdose; abuse, dependence, and severe withdrawal; anxiety, depressed mood, and suicidal thinking; high sodium load from sodium oxybate formulations
  • Speculative: Long-term cognitive harm from chronic nightly use in healthy adults

Monitoring

Marker Target Why
Epworth Sleepiness Scale No established target; track change from own baseline Marker expected to change
Blood pressure No established target; track change from own baseline Safety check for sodium load
Body weight No established target; track change from own baseline Marker reported to change; safety check
Alanine aminotransferase Local laboratory interval (standard reference range) Safety check for liver impairment

Cadence: During weekly titration, again after dose stabilization at about 6–12 weeks, and then every 6–12 months, with blood pressure and weight at each review

Qualitative Assessment

  • Night-time sleep quality and number of awakenings
  • Morning grogginess, confusion, or unsteadiness
  • Daytime alertness, energy, and cognitive clarity
  • Mood, anxiety, and any suicidal thinking
  • Episodes of bedwetting, sleepwalking, or unexplained night-time injury
  • Cataplexy frequency and inadvertent naps, where narcolepsy is the treated disorder